Ultragenyx Pharmaceutical (RARE) FCF Margin (2016 - 2026)

Ultragenyx Pharmaceutical (RARE) has 11 years of FCF Margin data on file, last reported at 145.59% in Q1 2026.

• On a quarterly basis, FCF Margin fell 2544.0% year-over-year to 145.59% in Q1 2026; TTM through Mar 2026 was 75.11%, a 665.0% decrease from a year earlier, with the FY2025 full-year figure at 70.13%, up 647.0% from the prior year.
• FCF Margin for Q1 2026 stood at 145.59%, down from 48.61% in the prior quarter.
• Over the last five years, FCF Margin for RARE reached as high as 40.45% in Q4 2023 and fell as low as 187.28% in Q1 2022.
• Historically, FCF Margin has averaged 105.01% across 5 years, with a median of 120.12% in 2023.
• Across the five-year window, FCF Margin slumped 16047 bps in 2022 and surged 13955 bps in 2023, its largest moves.
• Year by year, FCF Margin stood at 180.0% in 2022, then surged by 78 bps to 40.45% in 2023, then sank by 31 bps to 53.13% in 2024, then climbed by 9 bps to 48.61% in 2025, then slumped by 199 bps to 145.59% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 145.59% in Q1 2026, 48.61% in Q4 2025, and 57.96% in Q3 2025.